Supplementary Figure 2 from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive &lt;i&gt;TP53&lt;/i&gt;-mutant Ovarian Cancer